Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, has announced the granting of 14,000 restricted stock units to two new employees. The grants were approved by the company's Compensation Committee under the 2022 Inducement Plan, effective July 1, 2025.
The restricted stock units have a four-year vesting schedule, with 25% vesting annually, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Arcutis Biotherapeutics (Nasdaq: ARQT), un'azienda biofarmaceutica in fase commerciale specializzata in immuno-dermatologia, ha annunciato la concessione di 14.000 unità azionarie vincolate a due nuovi dipendenti. Le assegnazioni sono state approvate dal Comitato per la Retribuzione della società nell'ambito del Piano di Incentivazione 2022, con efficacia dal 1° luglio 2025.
Le unità azionarie vincolate seguono un calendario di maturazione quadriennale, con il 25% che matura ogni anno, subordinatamente alla continuità lavorativa. Questa concessione è stata effettuata in conformità alla Regola 5635(c)(4) del Nasdaq come incentivo all'assunzione.
Arcutis Biotherapeutics (Nasdaq: ARQT), una empresa biofarmacéutica en etapa comercial especializada en inmunodermatología, ha anunciado la concesión de 14,000 unidades restringidas de acciones a dos nuevos empleados. Las concesiones fueron aprobadas por el Comité de Compensación de la compañía bajo el Plan de Incentivos 2022, con vigencia a partir del 1 de julio de 2025.
Las unidades restringidas de acciones tienen un programa de adquisición de derechos de cuatro años, con un 25% que se adquiere anualmente, condicionado a la continuidad laboral. Esta concesión se realizó conforme a la Norma 5635(c)(4) de Nasdaq como incentivo para el empleo.
Arcutis Biotherapeutics (Nasdaq: ARQT)는 면역 피부학에 특화된 상업 단계의 생명공학 제약회사로, 두 명의 신입 직원에게 14,000개의 제한 주식 단위를 부여했다고 발표했습니다. 이 부여는 2022년 유인 계획에 따라 회사 보상 위원회에서 승인되었으며, 2025년 7월 1일부터 효력이 발생합니다.
제한 주식 단위는 4년간의 베스팅 일정을 따르며, 매년 25%씩 베스팅되며, 지속적인 고용이 조건입니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유인으로 이루어졌습니다.
Arcutis Biotherapeutics (Nasdaq : ARQT), une société biopharmaceutique en phase commerciale spécialisée en immunodermatologie, a annoncé l'attribution de 14 000 unités d'actions restreintes à deux nouveaux employés. Les attributions ont été approuvées par le comité de rémunération de la société dans le cadre du Plan d'Incitation 2022, effectif à partir du 1er juillet 2025.
Les unités d'actions restreintes suivent un calendrier d'acquisition de quatre ans, avec 25 % qui deviennent acquises chaque année, sous réserve d'une continuité d'emploi. Cette attribution a été effectuée conformément à la règle Nasdaq 5635(c)(4) en tant qu'incitation à l'emploi.
Arcutis Biotherapeutics (Nasdaq: ARQT), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Immun-Dermatologie spezialisiert hat, hat die Gewährung von 14.000 eingeschränkten Aktieneinheiten an zwei neue Mitarbeiter bekannt gegeben. Die Zuweisungen wurden vom Vergütungsausschuss des Unternehmens im Rahmen des Inducement-Plans 2022 genehmigt, wirksam ab dem 1. Juli 2025.
Die eingeschränkten Aktieneinheiten unterliegen einem Vierjahres-Vestingplan, bei dem jährlich 25 % vesten, abhängig von einer ununterbrochenen Anstellung. Diese Gewährung erfolgte gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Beschäftigungsanreiz.
- None.
- None.
WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 14,000 restricted stock units of Arcutis’ common stock to two newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates.
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to invent differentiated therapies against biologically validated targets, and has produced a robust pipeline with multiple follow-on clinical programs for a range of inflammatory dermatological conditions including atopic dermatitis and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
FAQ
What type of stock compensation did Arcutis Biotherapeutics (ARQT) grant to new employees in July 2025?
What is the vesting schedule for ARQT's July 2025 restricted stock unit grants?
Why did Arcutis Biotherapeutics issue these restricted stock units in July 2025?
When will the July 2025 ARQT restricted stock units begin vesting?
